SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

3/27/24 2:32:52 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CORT alert in real time by email

SC 13G/A 1 corthera13gaisdec2023.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 15 )* CORCEPT THERAPEUTICS, INC. ----------------------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------------------- (Title of Class of Securities) 218352102 -------------------- (CUSIP Number) 12/31/23 ---------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: / X / Rule 13d-1(b) / / Rule 13d-1(c) / / Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of thatsection of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. CUSIP No. 218352102 --------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). INGALLS & SNYDER, LLC 13-5156620 ------------------------------------------------------------ 2. Check the Appropriate Box if a Member of a Group (a) ----- (b) ----- 3. SEC Use Only --------------------------------------------- 4. Citizenship or Place of Organization New York ---------------------------------------- Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 0 -------------------------- 6. Shared Voting Power 0 -------------------------- 7. Sole Dispositive Power 0 -------------------------- 8. Shared Dispositive 8,262,476 -------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 8,262,476 --------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares --------- 11. Percent of Class Represented by Amount in Row (9) 8.0% --------- 12. Type of Reporting Person BD,IA --------- Item 1. (a) Name of Issuer CORCEPT THERAPEUTICS, INC. ----------------------------------------------------- (b) Address of Issuer's Principal Executive Offices 149 COMMONWEALTH DRIVE MENLO PARK, CA 94025 ------------------------------------------------------ Item 2. (a) Name of Persons Filing INGALLS & SNYDER, LLC ------------------------------------------------------- (b) Address of Principal Business Office or, if none, Residence 1325 AVEUNE OF THE AMERICAS, NEW YORK, NY 10019 ------------------------------------------------------- (c) Citizenship NEW YORK ------------------------------------------------------- (d) Title of Class of Securities COMMON STOCK ------------------------------------------------------- (e) CUSIP Number 218352102 ------------------------------------------------------- Item 3. This statement is filed pursuant to Rule 13d-1(b), and the Person Filing is a: (a) [X] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (e) [X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E); Item 4. Ownership (a) Amount beneficially owned: 8,262,476 (b) Percent of Class: 8.0% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 0 (iii)sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 8,262,476 Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the face that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following []. INAPPLICABLE Item 6. Ownership of More than Five Percent on Behalf of Another Person Ingalls & Snyder, LLC ("I&S") is a registered broker dealer and a registered investment advisor. Shares reported under shared dispositive power include shares held in accounts managed under investment advisory contracts. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company Not applicable. Item 8. Identification and Classification of Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief,the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer ofthe securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. March 22, 2024 ------------------------------- Date INGALLS & SNYDER, LLC By: /s/ Thomas O. Boucher, Jr. ------------------------------- Thomas O. Boucher, Jr. Manager

Get the next $CORT alert in real time by email

Recent Analyst Ratings for

$CORT

Date	Price Target	Rating	Analyst
11/6/2023	$29.00 → $38.00	Hold → Buy	Truist
4/11/2023	$25.00	Market Perform	SVB Securities
4/4/2023	$27.00	Overweight	Piper Sandler
2/15/2023	$35.00 → $22.00	Buy → Hold	Jefferies
8/1/2022	$30.00	Buy → Hold	Truist
7/27/2022	$21.00 → $35.00	Hold → Buy	Jefferies
6/27/2022	$30.00 → $34.00	Buy	Canaccord Genuity
2/2/2022	$30.00	Buy	Canaccord Genuity

More analyst ratings

SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

3/27/24 2:32:52 PM ET

$CORT

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CORT alert in real time by email

Recent Analyst Ratings for

$CORT

Date	Price Target	Rating	Analyst
11/6/2023	$29.00 → $38.00	Hold → Buy	Truist
4/11/2023	$25.00	Market Perform	SVB Securities
4/4/2023	$27.00	Overweight	Piper Sandler
2/15/2023	$35.00 → $22.00	Buy → Hold	Jefferies
8/1/2022	$30.00	Buy → Hold	Truist
7/27/2022	$21.00 → $35.00	Hold → Buy	Jefferies
6/27/2022	$30.00 → $34.00	Buy	Canaccord Genuity
2/2/2022	$30.00	Buy	Canaccord Genuity

More analyst ratings

SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$CORT

SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$CORT

$CORT
Analyst Ratings

Corcept Therapeutics upgraded by Truist with a new price target

SVB Securities initiated coverage on Corcept Therapeutics with a new price target

Piper Sandler initiated coverage on Corcept Therapeutics with a new price target

$CORT
SEC Filings

SEC Form 8-K filed by Corcept Therapeutics Incorporated

SEC Form 10-Q filed by Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

$CORT
Press Releases

Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025

FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

$CORT
Insider Trading

Chief Development Officer Guyer William gifted 200 shares, decreasing direct ownership by 4% to 5,287 units (SEC Form 4)

Director Cannon Gillian gifted 7,393 shares, closing all direct ownership in the company (SEC Form 4)

Director Swisher Daniel N Jr exercised 2,200 shares at a strike of $14.08 and sold $159,390 worth of shares (2,200 units at $72.45) (SEC Form 4)

$CORT
Leadership Updates

Corcept Appoints Roberto Vieira as President, Oncology

Corcept Appoints Monica Tellado as President, Emerging Markets

Corcept Therapeutics Announces Appointment of Three Senior Leaders

$CORT
Financials

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

$CORT
Large Ownership Changes